Protalix announces five poster presentations at Fabry Disease conference

Protalix BioTherapeutics, Inc.

Posters cover pegunigalsidase alfa data from BALANCE, BRIDGE, BRIGHT, and extension studies.
Conference is the 7th Update on Fabry Disease in Würzburg, Germany, May 29-31, 2022.
Posters and abstracts will be posted on Protalix's website under Investors/Presentations.
Data include 24-month renal function results from Phase III BALANCE study.
No specific efficacy or safety numbers were disclosed in the press release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.